Serum markers for melanoma;Serummarker des malignen melanoms

Hautarzt

Volumn 56, Issue 2, 2005, Pages 173-186

  Ugurel, S ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Disease monitoring; Follow up; Malignant melanoma; Prognosis; Serum markers

Indexed keywords

LACTATE DEHYDROGENASE; PROTEIN S100B; TUMOR MARKER;

BLOOD LEVEL; CANCER PATIENT; CANCER SURVIVAL; CLINICAL FEATURE; CORRELATION ANALYSIS; DISEASE COURSE; FOLLOW UP; HUMAN; MELANOMA; PROGNOSIS; REVIEW; SURVIVAL RATE; TUMOR GROWTH;

DISEASE PROGRESSION; EXTRACELLULAR MATRIX PROTEINS; FOLLOW-UP STUDIES; HUMANS; L-LACTATE DEHYDROGENASE; LYMPH NODES; MELANOMA; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NERVE GROWTH FACTORS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEINS; REFERENCE VALUES; S100 PROTEINS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 17644414651     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-004-0893-2     Document Type: Review

References (15)

1. Balch CM, Buzaid AC, Soong SJ et al. (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19: 3635-3648
2. Bosserhoff AK, Kaufmann M, Kaluza B et al. (1997) Melanoma-inhibitory activity, a novel serum marker for progression of malignant melanoma. Cancer Res 57: 3149-3153
3. Boyano MD, Garcia-Vazquez MD, Lopez-Michelena T et al. (2000) Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. Br J Cancer 83: 847-852
4. Deichmann M, Kahle B, Moser K, Wacker J, Wust K (2004) Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer 91: 699-702
5. Djukanovic D, Hofmann U, Sucker A, Schadendorf D (2001) Melanoma tumour markers S100B and MIA: evaluation of stability in serum and blood upon storageand processing. Br J Dermatol 145: 1030-1031
6. Garbe C, Schadendorf D (2003) Malignes Melanom - Neue Daten und Konzepte zur Nachsorge. Dtsch Ärztebl 100: 1804-1808
7. Garbe C, Leiter U, Ellwanger U, Blaheta HJ, Meier F, Rassner G, Schittek B (2003) Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription- polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 97: 1737-1745
8. Guo HB, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmuller D (1995) Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer 31A: 924-928
9. Hauschild A, Engel G, Brenner W, Glaeser R, Moenig H, Henze E, Christophers E (1999) Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/ or immunotherapy. Br J Dermatol 140: 1065-1071
10. Jury CS, McAllister EJ, MacKie RM (2000) Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol 143: 269-274
11. Mian S, Ugurel S, Parkinson E et al. (in press) Serum fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol in press
12. Rebmann V, Ugurel S, Tilgen W, Reinhold U, Grosse-Wilde H (2002) Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients. Int J Cancer 100: 580-585
13. Schultz ES, Diepgen TL, Von Den Driesch P (1998) Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. Br J Dermatol 138: 426-430
14. Ugurel S, Rappl G, Tilgen W, Reinhold U (2001) Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 19: 577-583
15. Vuoristo MS, Laine S, Huhtala H et al. (2001) Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma. Eur J Cancer 37: 1629-1634